Related Experiment Video
Updated: Aug 8, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
[Clinico-immunologic effect of tactivin in chronic myeloid leukemia]
Abstract:
Immunological reactivity and factors of nonspecific body defense were studied in 35 patients with advanced chronic myeloid leukemia (CML). Prior to cytostatic therapy, CML patients have secondary combined immunodeficiency manifesting by inhibition of T-system immunity and phagocytic neutrophil activity. Repeated courses of myelosan chemotherapy aggravate the above immune defects. The adjuvant immunomodulator tactivin corrects cellular immunity and reduces the occurrence of infectious complications 1.77-fold.
More Related Videos
Related Concept Videos
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Tumor Immunotherapy
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Therapeutic Drug Monitoring: Affecting Factors

